Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by t…
This bill, the "Patients Deserve Price Tags Act," substantially expands federal health care price-transparency requirements across hospitals, clinical diagnostic laboratories, imaging providers, ambulatory surgical centers, health plans, and group health plan service providers. It requires machine-readable and consumer-friendly public disclosure of gross charges, discounted cash prices, payer-specific negotiated rates (with plan and payer names), and de-identified maximum/minimum negotiated charges, and directs the HHS Secretary to issue standard formats by specified deadlines.
Scope and intrusiveness: liberals and centrists accept broad federal disclosure mandates; conservatives view them as federal overreach.
Relative to its intended legislative type, this bill is a detailed substantive policy reform focused on healthcare price transparency that is precise about required disclosures, formats, timelines, enforcement, and statutory integration, but it omits fiscal/resourcing provisions and defers significant operational detail to future rulemaking.
This bill, the "Patients Deserve Price Tags Act," substantially expands federal health care price-transparency requirements across hospitals, clinical diagnostic laboratories, imaging providers, ambulatory surgical centers, health plans, and group health plan service providers.
It requires machine-readable and consumer-friendly public disclosure of gross charges, discounted cash prices, payer-specific negotiated rates (with plan and payer names), and de-identified maximum/minimum negotiated charges, and directs the HHS Secretary to issue standard formats by specified deadlines.
The bill strengthens enforcement by requiring senior attestation, establishing regular compliance monitoring, and authorizing civil monetary penalties (variously scaled by entity type and size), and it adds new requirements for explanations of benefits and itemized billing before collections actions.
Judged only by content and structure, the bill is a large, detailed overhaul of price transparency with significant compliance and enforcement obligations that directly challenge major industry practices. While the goal (price transparency) has public appeal and some bipartisan support in principle, the bill's breadth, intrusive disclosure of negotiated contracts, heavy penalties, and multi‑agency rulemaking create powerful incentives for affected industries to seek amendments, legal challenges, or congressional compromise. Those factors make enactment in this exact form unlikely without substantial negotiation or narrowing.
Relative to its intended legislative type, this bill is a detailed substantive policy reform focused on healthcare price transparency that is precise about required disclosures, formats, timelines, enforcement, and statutory integration, but it omits fiscal/resourcing provisions and defers significant operational detail to future rulemaking.
Scope and intrusiveness: liberals and centrists accept broad federal disclosure mandates; conservatives view them as federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and intrusiveness: liberals and centrists accept broad federal disclosure mandates; conservatives view them as federal overreach.
A mainstream liberal/left-leaning person would likely view the bill favorably as a concrete step toward empowering patients, reducing surprise or opaque pricing, and improving accountability in health care markets.
They would welcome the broad scope (hospitals, labs, imaging, ambulatory centers, and plans) and the requirements for consumer-friendly displays, attestation, and enforcement.
They would see this as advancing equity by requiring charity care info and binding discounted cash prices for self-pay patients, while also valuing the prohibitions on gag clauses to allow plans and plan sponsors to audit vendors.
A centrist/moderate would likely welcome the bill's goal of increasing price transparency because it targets information asymmetries that harm consumers and employers, but they would be pragmatic about tradeoffs.
They would appreciate machine-readable standards and plan-level access to claims data, while worrying about implementation complexity, administrative costs, and unintended consequences.
They would look for detailed, pragmatic rulemaking, adequate transition periods, safeguards against over-disclosure of proprietary contract terms, and clear auditing and enforcement procedures to avoid gaming or litigation.
A mainstream conservative would be skeptical of the bill despite nominal support for transparency.
They would object to extensive federal mandates on private contracts and pricing disclosures, the broad scope of HHS rulemaking authority, and steep civil penalties that they would view as government overreach.
They would be particularly concerned about mandatory disclosure of payer-specific negotiated rates and contractual algorithms, potential harm to competitive bargaining, and the heavy-handed prohibition of contract terms.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Judged only by content and structure, the bill is a large, detailed overhaul of price transparency with significant compliance and enforcement obligations that directly challenge major industry practices. While the goal (price transparency) has public appeal and some bipartisan support in principle, the bill's breadth, intrusive disclosure of negotiated contracts, heavy penalties, and multi‑agency rulemaking create powerful incentives for affected industries to seek amendments, legal challenges, or congressional compromise. Those factors make enactment in this exact form unlikely without substantial negotiation or narrowing.
The bill has not accumulated any surfaced votes yet.
Scope and intrusiveness: liberals and centrists accept broad federal disclosure mandates; conservatives view them as federal overreach.
Judged only by content and structure, the bill is a large, detailed overhaul of price transparency with significant compliance and enforcem…
Relative to its intended legislative type, this bill is a detailed substantive policy reform focused on healthcare price transparency that is precise about required disclosures, formats, timelines, enforcement, and stat…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.